					(Based on PTO 03-08 versio	
Substitute for form 1449/PTO				Complete if Known		
500	Stitute for form 1449/FTO			Application Number	10/815,481	
INFORMATION DISCLOSURE				Filing Date	March 31, 2004	
STATEMENT BY APPLICANT				First Named Inventor	Rajesh A. PATEL	
Ŭ		• • •		Art Unit	1618	
	(Use as many she	eets a	necessary)	Examiner Name	E. Silverman	
Sheet	1	of	1	Attorney Docket Number	304142000900	

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY		Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1.	US-4 670 014	06-02-1987	Hue et al.	

	FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code [†] -Number [‡] -Kind Code [‡] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶			
	2	EP 0 153 896-A2 A3 R1	09-04-1985	Centre Technique du Cuir	Translation of				
					Abstract Only.				
	3.	WO-03/101358-A1	12-11-2003	Titan Pharmaceuticals, Inc.					

Examiner	Date
Signature	Considered

"EXAMINER Initial if information considered, whether or not cliation is in conformance with MPEP 698. Draw line through cliation if not in conformance and not considered, include copy of this form with next communication to applicant." Applicant's unique cliation designation number (optional). "See Kride Cooks of USEP'09 640. "Event of College and Conference and applications of MPEP'09 clinical 513," Event officials talks used the sciournate. The three-left one College for the College for Coll

	NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²		
		Anonymous. (Date Unknown). "NSAIDs Traditional NSAIDs," located at			
	4.	<ntip: chart_nsalds.asp="" conditions="" drugguide="" www.arunritis.org="">, last visited on march 27, 2003, 4 pages.</ntip:>			
	5.	Anonymous. (December 14, 2002). "India Infoline Sector Reports Pharmaceuticals," located at http://www.inidainfoline.com/sect/phfo/ch21.html , last visited March 27, 2003, 2 pages.			
	6.	Bibblani, F. et al. (Date Unknown). "Continuous Apomorphine Administration with Novel EVA Implants Reduces the Risks of Motor Compilations Compared to Pulsatille Apormorphine in L- DOPA-Native, MPTP-Lesioned Primates," Abstract Preview: AAN3L_1225, located at http://www.abstracts-on-line.com , last visited on February 6, 2003, 1 page			
	7.	DURING, M.J. et al. (April 1989). "Controlled Release of Dopamine from a Polymeric Brain Implant: In Vivo Characterization," Ann. Neurol. 25(4):351-356.			
	8.	HARDMAN, J.G. et al. eds. (2001). "Dopamine-Receptor Agonists," in <u>Goodman & Gilman's The Pharmacological Basis of Therapeutics</u> , Tenth Edition, McGraw-Hill: New York, NY, pp. 557-558.			
	9.	HARDMAN, J.G. et al. eds. (2001). "Levodopa," in Goodman & Gilman's The Pharmacological Basis of Therapeutics, Tenth Edition, McGraw-Hill: New York, NY, pp. 555-557.			

Examiner Signature	/Eric Silverman/ (07/16/2008)	Date Considered	

^{*}EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.